Antinociceptive effects of high-dose remifentanil in male methadone-maintained patients.
The treatment of acute pain in patients maintained on methadone is difficult due to increased pain sensitivity (hyperalgesia) and cross-tolerance to other opioids. This study aimed to investigate whether remifentanil elicits antinociception in methadone-maintained subjects in a dose-dependent manner. Eight chronic methadone-maintained subjects attended the testing session approximately 20 h after their normal methadone dose (range 50-110 mgday(-1)). Following a 20 min saline infusion, subjects were administered intravenous remifentanil in seven increasing doses ranging from 0.5 to 3.5 microgkg(-1)min(-1), each for 2 0min. Testing was performed in the last 10 min of each infusion. The testing measures included nociception, as measured by the cold pressor test, withdrawal using the subjective opiate withdrawal scale (SOWS), and subjective opioid effects using the morphine-benzedrine group scale (MBG). Results showed dose-dependent increase in cold pressor tolerance time from baseline of 15.6+/-3.5 (mean+/-SEM)s up to 77.3+/-24.7s during this dosing protocol. During the infusion typical mu-opioid receptor agonist side effects were observed, but with no withdrawal. Methadone-maintained patients demonstrate significant tolerance to remifentanil and may require opioid doses 20-30 higher than required for the treatment of acute pain in opioid-naïve patients.
Hay
Justin L
JL
Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, SA 5005, Australia. justin.hay@alumni.adelaide.edu.au
White
Jason M
JM
Bochner
Felix
F
Somogyi
Andrew A
AA
D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003080:Cold Temperature / Q000009:adverse effects; D004347:Drug Interactions; D004361:Drug Tolerance; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008691:Methadone / Q000494:pharmacology* / Q000627:therapeutic use; D009293:Opioid-Related Disorders / Q000503:physiopathology / Q000534:rehabilitation*; D010146:Pain / Q000209:etiology / Q000517:prevention & control*; D010147:Pain Measurement; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000077208:Remifentanil
D000701:Analgesics, Opioid; D010880:Piperidines; D000077208:Remifentanil; D008691:Methadone